Ramipril
Brand names: Ramipril, Altace
At a glance
- Medicare prescriptions, 2024
- 1,053,574
- Medicare drug cost
- $11.7M
- Average cost per prescription
- $11.15
- Clinicians who prescribed it
- 41,194
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Ramipril capsules are an angiotensin converting enzyme (ACE) inhibitor indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It may be used alone or in combination with thiazide diuretics. In patients 55 years or older at high risk of developing a major cardiovascular event, ramipril capsules
From the FDA-approved prescribing information (label dated September 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue ramipril as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning When pregnancy is detected, discontinue ramipril as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Internal Medicine 29.5%
- Family Medicine 29.1%
- Cardiology 16.0%
- Nurse Practitioners 9.0%
- Interventional Cardiology 4.7%
- Physician Assistants 3.6%
- Endocrinology & Diabetes 1.9%
- General Practice 1.9%
- Geriatric Medicine 1.1%
- Nephrology (Kidney) 1.0%
- Cardiac Electrophysiology 0.4%
- Pulmonology 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 22% from 2019 to 2024.
Biggest change by state since 2019
- Delaware −5%
- Massachusetts −5%
- Utah −6%
- Washington −6%
- Maryland −9%
- West Virginia (smallest change) −32%
- Mississippi (smallest change) −31%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 3 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Bluepoint Laboratories
| Strength | Looks like | Imprint |
|---|---|---|
| 1.25 mg | yellow capsule, 15 mm | D 05 |
| 2.5 mg | orange capsule, 15 mm | D 06 |
| 5 mg | red capsule, 15 mm | D 07 |
| 10 mg | blue capsule, 15 mm | D 08 |
Bryant Ranch Prepack
| Strength | Looks like | Imprint |
|---|---|---|
| 5 mg | red capsule, 15 mm | D 07 |
Rising Pharma Holdings, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 1.25 mg | yellow capsule, 15 mm | D 05 |
| 2.5 mg | orange capsule, 15 mm | D 06 |
| 5 mg | red capsule, 15 mm | D 07 |
| 10 mg | blue capsule, 15 mm | D 08 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
2 recalls since 2020
- Aug 2026 · Hikma Pharmaceuticals USA Inc. · Class II
Failed Impurities/Degradation Specifications: OOS result obtained for a process impurity, dicyclohexylurea (DCU). - Oct 2024 · Lupin Pharmaceuticals Inc. · Class II
CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.